NTLA
HealthcareIntellia Therapeutics, Inc.
$9.37
+$0.16 (+1.74%)
Jan 5, 2026
Price History (1Y)
Analysis
Intellia Therapeutics, Inc. is a biotechnology company in the healthcare sector with 403 employees. With a market capitalization of $1.09B, the company's scale is significant within its industry. The financial health of Intellia Therapeutics indicates challenges in profitability, with gross margin at 0.0%, operating margin at -808.9%, and profit margin also at 0.0%. Returns on equity (-52.1%) and assets (-28.5%) are negative, suggesting that the company is generating losses rather than profits. The balance sheet shows a debt-to-equity ratio of 13.09, indicating a moderate level of indebtedness. However, the company has substantial cash reserves at $511.04M. The valuation context for Intellia Therapeutics is marked by a forward P/E ratio of -2.61 and an EV/EBITDA ratio of -1.40, suggesting that investors are currently valuing the company's earnings potential quite low. The revenue growth rate has been 51.3% year-over-year, which may be a positive indicator for future performance. Dividend information is not applicable, as the dividend yield and payout ratio are both N/A.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $1.09B
- P/E Ratio
- N/A
- 52-Week High
- $28.25
- 52-Week Low
- $5.90
- Avg Volume
- 7.01M
- Beta
- 2.06
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 403